Recent Advances in Thalassemia Research: A Comprehensive Assessment From Diagnostic Technologies to Clinical Treatment.

IF 2.9 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY
Chaoqiong Zhou, Ting Chen, Ying Huang, Huali Wang, Dahai He, Feng Wu, Yan Zhang, Lirui Kong
{"title":"Recent Advances in Thalassemia Research: A Comprehensive Assessment From Diagnostic Technologies to Clinical Treatment.","authors":"Chaoqiong Zhou, Ting Chen, Ying Huang, Huali Wang, Dahai He, Feng Wu, Yan Zhang, Lirui Kong","doi":"10.1002/jcla.70228","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Thalassemia is a common hereditary blood disorder characterized by impaired globin synthesis, leading to anemia and a variety of related complications. With the rapid advances in genomics and molecular biology, remarkable progress has been made in this field in recent years, especially in the in-depth exploration of genetic mechanisms, the innovation of diagnostic techniques and the continuous update of therapeutic strategies. It is worth noting that with the emergence of new treatment strategies such as gene therapy and stem cell transplantation, offer new hope for patients. Despite significant progress, further research is needed to address the limitations of existing treatment methods and optimize long-term management for patients.</p><p><strong>Methods: </strong>This review introduces the epidemiology, pathogenic mechanisms, and related complications of thalassemia.</p><p><strong>Results: </strong>It also highlights innovations in the diagnosis of thalassemia (such as TGS and Genomics technologies) and treatment advancements (such as CRISPR/Cas9, HSCT, and Luspatercept) and their limitations, and explores why transformative tools have not been fully utilized in regions with high prevalence of thalassemia.</p><p><strong>Conclusions: </strong>Unlike existing reviews that focus solely on either diagnostic or therapeutic aspects, this article integrates both perspectives with an emphasis on clinical accessibility. It aims to provide sustainable and equitable management guidance for clinicians, researchers, and policymakers involved in thalassemia care.</p>","PeriodicalId":15509,"journal":{"name":"Journal of Clinical Laboratory Analysis","volume":" ","pages":"e70228"},"PeriodicalIF":2.9000,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Laboratory Analysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jcla.70228","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Thalassemia is a common hereditary blood disorder characterized by impaired globin synthesis, leading to anemia and a variety of related complications. With the rapid advances in genomics and molecular biology, remarkable progress has been made in this field in recent years, especially in the in-depth exploration of genetic mechanisms, the innovation of diagnostic techniques and the continuous update of therapeutic strategies. It is worth noting that with the emergence of new treatment strategies such as gene therapy and stem cell transplantation, offer new hope for patients. Despite significant progress, further research is needed to address the limitations of existing treatment methods and optimize long-term management for patients.

Methods: This review introduces the epidemiology, pathogenic mechanisms, and related complications of thalassemia.

Results: It also highlights innovations in the diagnosis of thalassemia (such as TGS and Genomics technologies) and treatment advancements (such as CRISPR/Cas9, HSCT, and Luspatercept) and their limitations, and explores why transformative tools have not been fully utilized in regions with high prevalence of thalassemia.

Conclusions: Unlike existing reviews that focus solely on either diagnostic or therapeutic aspects, this article integrates both perspectives with an emphasis on clinical accessibility. It aims to provide sustainable and equitable management guidance for clinicians, researchers, and policymakers involved in thalassemia care.

地中海贫血研究的最新进展:从诊断技术到临床治疗的综合评估。
背景:地中海贫血是一种常见的遗传性血液疾病,其特征是珠蛋白合成受损,导致贫血和各种相关并发症。随着基因组学和分子生物学的快速发展,近年来该领域取得了令人瞩目的进展,特别是对遗传机制的深入探索、诊断技术的创新和治疗策略的不断更新。值得注意的是,随着基因治疗和干细胞移植等新的治疗策略的出现,为患者提供了新的希望。尽管取得了重大进展,但需要进一步研究以解决现有治疗方法的局限性并优化患者的长期管理。方法:综述地中海贫血的流行病学、发病机制及相关并发症。结果:它还强调了地中海贫血诊断方面的创新(如TGS和Genomics技术)和治疗方面的进步(如CRISPR/Cas9、HSCT和Luspatercept)及其局限性,并探讨了为什么在地中海贫血高发地区没有充分利用变革性工具。结论:不像现有的综述只关注诊断或治疗方面,这篇文章整合了两种观点,强调临床可及性。它旨在为参与地中海贫血护理的临床医生、研究人员和决策者提供可持续和公平的管理指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Laboratory Analysis
Journal of Clinical Laboratory Analysis 医学-医学实验技术
CiteScore
5.60
自引率
7.40%
发文量
584
审稿时长
6-12 weeks
期刊介绍: Journal of Clinical Laboratory Analysis publishes original articles on newly developing modes of technology and laboratory assays, with emphasis on their application in current and future clinical laboratory testing. This includes reports from the following fields: immunochemistry and toxicology, hematology and hematopathology, immunopathology, molecular diagnostics, microbiology, genetic testing, immunohematology, and clinical chemistry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书